Owen, Rhiannon K. http://orcid.org/0000-0001-5977-376X
Bujkiewicz, Sylwia
Tincello, Douglas G.
Abrams, Keith R.
Article History
Received: 27 December 2019
Accepted: 20 May 2020
First Online: 8 July 2020
Ethics approval and consent to participate
: Not applicable.
: Not applicable.
: RKO has served as a paid consultant, providing methodological advice to Astellas, Creativ-Ceutical, Cogentia, Daiichi Sankyo, NICE, Roche, and Vifor. She is a member of the NICE Technology Appraisal Committee. SB has served as a paid consultant, providing methodological advice, to NICE and Roche, and has received research funding from European Federation of Pharmaceutical Industries & Associations (EFPIA) and Johnson & Johnson. DGT has served as a paid consultant with Femeda, SynerMed, Cambridge Medical Robotics, and Allergan in the last 10 years. KRA has served as a paid consultant, providing methodological advice, to; Abbvie, Amaris, Allergan, Astellas, AstraZeneca, Boehringer Ingelheim, Bristol-Meyers Squibb, Creativ-Ceutical, GSK, ICON/Oxford Outcomes, Ipsen, Janssen, Eli Lilly, Merck, NICE, Novartis, NovoNordisk, Pfizer, PRMA, Roche and Takeda, and has received research funding from Association of the British Pharmaceutical Industry (ABPI), European Federation of Pharmaceutical Industries & Associations (EFPIA), Pfizer and Sanofi and Swiss Precision Diagnostics. He is a Partner and Director of Visible Analytics Limited, a healthcare consultancy company.